Key signaling pathways in thyroid cancer

Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013

(2017) Hyeyeun Lim et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease

(2017) Miguel Melo et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine

(2016) James Nagarajah et al.   JOURNAL OF CLINICAL INVESTIGATION

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers

(2016) Iñigo Landa et al.   JOURNAL OF CLINICAL INVESTIGATION

A Detailed Clinicopathologic Study of ALK-translocated Papillary Thyroid Carcinoma

(2015) Angela Chou et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Association ofTERTPromoter Mutation 1,295,228 C>T WithBRAFV600E Mutation, Older Patient Age, and Distant Metastasis in Anaplastic Thyroid Cancer

(2015) Xiaoguang Shi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer

(2015) Mingzhao Xing et al.   JOURNAL OF CLINICAL ONCOLOGY

Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase–Rearranged Anaplastic Thyroid Carcinoma

(2015) Yann Godbert et al.   JOURNAL OF CLINICAL ONCOLOGY

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

(2015) Andrea Sartore-Bianchi et al.   JNCI-Journal of the National Cancer Institute

Regulation of RAF protein kinases in ERK signalling

(2015) Hugo Lavoie et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

(2015) Martin Schlumberger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

(2015) Andrea Sartore-Bianchi et al.   JNCI-Journal of the National Cancer Institute

Integrated Genomic Characterization of Papillary Thyroid Carcinoma

(2014) Nishant Agrawal et al.   CELL

Identification of a Novel HIP1-ALK Fusion Variant in Non–Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib

(2014) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

(2014) Marcia S Brose et al.   LANCET

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer

(2014) L. M. Kelly et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer

(2013) Rebecca J. Leeman-Neill et al.   CANCER

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models

(2013) Kiyoshi Okamoto et al.   CANCER LETTERS

Recent Insights into the Cell Biology of Thyroid Angiofollicular Units

(2013) Ides M. Colin et al.   ENDOCRINE REVIEWS

Highly prevalent TERT promoter mutations in aggressive thyroid cancers

(2013) Xiaoli Liu et al.   ENDOCRINE-RELATED CANCER

Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer

(2013) Mingzhao Xing et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Frequent SomaticTERTPromoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease

(2013) Iñigo Landa et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer

(2013) Alan L. Ho et al.   NEW ENGLAND JOURNAL OF MEDICINE

TERT Promoter Mutations in Familial and Sporadic Melanoma

(2013) S. Horn et al.   SCIENCE

Highly Recurrent TERT Promoter Mutations in Human Melanoma

(2013) F. W. Huang et al.   SCIENCE

Frequency of TERT promoter mutations in human cancers

(2013) João Vinagre et al.   Nature Communications

Abstract 4403: Differential cytotoxic effects of atorvastatin in human hepatocellular carcinoma and pancreatic adenocarcinoma cells

(2012) Maria B. Lai et al.   CANCER RESEARCH

A Comprehensive Survey of Ras Mutations in Cancer

(2012) I. A. Prior et al.   CANCER RESEARCH

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

FOXO1 Controls Thyroid Cell Proliferation in Response to TSH and IGF-I and Is Involved in Thyroid Tumorigenesis

(2012) Miguel A. Zaballos et al.   MOLECULAR ENDOCRINOLOGY

Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110  (PIK3CA)

(2012) J. E. Burke et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rearranged Anaplastic Lymphoma Kinase (ALK) Gene in Adult-Onset Papillary Thyroid Cancer Amongst Atomic Bomb Survivors

(2012) Kiyohiro Hamatani et al.   THYROID

Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells

(2011) Peng Hou et al.   ENDOCRINE-RELATED CANCER

Pioglitazone Induces a Proadipogenic Antitumor Response in Mice with PAX8-PPARγ Fusion Protein Thyroid Carcinoma

(2011) Melissa E. Dobson et al.   ENDOCRINOLOGY

High Growth Rate of Benign Thyroid Nodules BearingRET/PTCRearrangements

(2011) Maria Rosaria Sapio et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway

(2011) Ruixin Liu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

GDC-0941 Inhibits Metastatic Characteristics of Thyroid Carcinomas by Targeting both the Phosphoinositide-3 Kinase (PI3K) and Hypoxia-Inducible Factor-1α (HIF-1α) Pathways

(2011) Natalie Burrows et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Ras trafficking, localization and compartmentalized signalling

(2011) Ian A. Prior et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma

(2010) Libero Santarpia et al.   CANCER

Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer

(2010) Celine J. Guigon et al.   CARCINOGENESIS

The emerging mechanisms of isoform-specific PI3K signalling

(2010) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells

(2010) M Gandhi et al.   ONCOGENE

Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling

(2009) D. A. Ritt et al.   MOLECULAR AND CELLULAR BIOLOGY

The complexity of mitogen-activated protein kinases (MAPKs) made simple

(2008) M. Krishna et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer

(2008) C. Romei et al.   ENDOCRINE-RELATED CANCER

Highly Prevalent Genetic Alterations in Receptor Tyrosine Kinases and Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase Pathways in Anaplastic and Follicular Thyroid Cancers

(2008) Zhi Liu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†

(2008) Adrian J. Folkes et al.   JOURNAL OF MEDICINAL CHEMISTRY

Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon

(2008) Kevin M Haigis et al.   NATURE GENETICS

PTEN-deficient cancers depend on PIK3CB

(2008) S. Wee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Role of the PAX8/PPARγFusion Oncogene in Thyroid Cancer

(2008) Kimberly A. Placzkowski et al.   PPAR Research